Autoinflammatory and autoimmune conditions at the crossroad of COVID-19.
J Autoimmun
; 114: 102506, 2020 11.
Article
in En
| MEDLINE
| ID: mdl-32563547
ABSTRACT
Coronavirus disease 2019 (COVID-19) has been categorized as evolving in overlapping phases. First, there is a viral phase that may well be asymptomatic or mild in the majority, perhaps 80% of patients. The pathophysiological mechanisms resulting in minimal disease in this initial phase are not well known. In the remaining 20% of cases, the disease may become severe and/or critical. In most patients of this latter group, there is a phase characterized by the hyperresponsiveness of the immune system. A third phase corresponds to a state of hypercoagulability. Finally, in the fourth stage organ injury and failure occur. Appearance of autoinflammatory/autoimmune phenomena in patients with COVID-19 calls attention for the development of new strategies for the management of life-threatening conditions in critically ill patients. Antiphospholipid syndrome, autoimmune cytopenia, Guillain-Barré syndrome and Kawasaki disease have each been reported in patients with COVID-19. Here we present a scoping review of the relevant immunological findings in COVID-19 as well as the current reports about autoinflammatory/autoimmune conditions associated with the disease. These observations have crucial therapeutic implications since immunomodulatory drugs are at present the most likely best candidates for COVID-19 therapy. Clinicians should be aware of these conditions in patients with COVID-19, and these observations should be considered in the current development of vaccines.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Autoimmune Diseases
/
Coronavirus Infections
/
Betacoronavirus
/
Cytokine Release Syndrome
Type of study:
Diagnostic_studies
/
Etiology_studies
/
Risk_factors_studies
Language:
En
Year:
2020
Type:
Article